CoChat
Sign Up
Cited by 50Gut microbiota and healthOral microbiology and periodontitis researchProbiotics and Fermented Foods

Harness the functions of gut microbiome in tumorigenesis for cancer treatment

Open access
Lee, Mong‐Hong·2021·Cancer Communications
DOI 10.1002/cac2.12200PMC PMC8504147
Open this paper in CoChat — free accountOpen PDF

Abstract

It has been shown that gut microbiota dysbiosis leads to physiological changes and links to a number of diseases, including cancers. Thus, many cancer categories and treatment regimens should be investigated in the context of the microbiome. Owing to the availability of metagenome sequencing and multiomics studies, analyses of species characterization, host genetic changes, and metabolic profile of gut microbiota have become feasible, which has facilitated an exponential knowledge gain about microbiota composition, taxonomic alterations, and host interactions during tumorigenesis. However, the complexity of the gut microbiota, with a plethora of uncharacterized host‐microbe, microbe‐microbe, and environmental interactions, still contributes to the challenge of advancing our knowledge of the microbiota‐cancer interactions. These interactions manifest in signaling relay, metabolism, immunity, tumor development, genetic instability, sensitivity to cancer chemotherapy and immunotherapy. This review summarizes current studies/molecular mechanisms regarding the association between the gut microbiota and the development of cancers, which provides insights into the therapeutic strategies that could be harnessed for cancer diagnosis, treatment, or prevention.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cac2.12200

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The gut microbiome is a modifiable risk factor in multiple cancer types, including colorectal, gastric, and pancreatic cancers.

    “The gut microbiome is increasingly recognized as a modifiable risk factor in multiple cancer types, including colorectal, gastric, and pancreatic cancers [12,41–43]”

    From Phage therapy in oncology: opportunities for cancer prevention and treatment (2026) · cites this paper as [42]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

No citation lists for this paper

No citation lists for this paper yet — checked again daily.

References 269 · Cited by 50

Research works printed but not linked: 218

  1. [1]Fischbach MA. Microbiome: Focus on Causation and Mechanism. Cell. 2018; 174(4): 785‐ 790. 30096310 PMC6094951
  2. [2]Sender R, Fuchs S, Milo R. Revised Estimates for the Number of Human and Bacteria Cells in the Body. PLoS Biol. 2016; 14(8): e1002533. 27541692 PMC4991899
  3. [4]Rajagopala SV, Vashee S, Oldfield LM, Suzuki Y, Venter JC, Telenti A, et al. The Human Microbiome and Cancer. Cancer Prev Res (Phila). 2017; 10(4): 226‐ 34. 28096237
  4. [5]Bhatt AP, Redinbo MR, Bultman SJ. The role of the microbiome in cancer development and therapy. CA Cancer J Clin. 2017; 67(4): 326‐ 44. 28481406 PMC5530583
  5. [6]Zou S, Fang L, Lee MH. Dysbiosis of gut microbiota in promoting the development of colorectal cancer. Gastroenterol Rep (Oxf). 2018; 6(1): 1‐ 12. 29479437 PMC5806407
  6. [10]de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012; 13(6): 607‐ 15. 22575588
  7. [12]Poore GD, Kopylova E, Zhu Q, Carpenter C, Fraraccio S, Wandro S, et al. Microbiome analyses of blood and tissues suggest cancer diagnostic approach. Nature. 2020; 579(7800): 567‐ 74. 32214244 PMC7500457
  8. [13]Dohlman AB, Arguijo Mendoza D, Ding S, Gao M, Dressman H, Iliev ID, et al. The cancer microbiome atlas: a pan‐cancer comparative analysis to distinguish tissue‐resident microbiota from contaminants. Cell Host Microbe. 2021; 29(2): 281‐ 98.e5. 33382980 PMC7878430
  9. [14]Stewart OA, Wu F, Chen Y. The role of gastric microbiota in gastric cancer. Gut Microbes. 2020; 11(5): 1220‐ 30. 32449430 PMC7524314
  10. [15]Ferreira RM, Pereira‐Marques J, Pinto‐Ribeiro I, Costa JL, Carneiro F, Machado JC, et al. Gastric microbial community profiling reveals a dysbiotic cancer‐associated microbiota. Gut. 2018; 67(2): 226‐ 36. 29102920 PMC5868293
  11. [16]Sayed IM, Sahan AZ, Venkova T, Chakraborty A, Mukhopadhyay D, Bimczok D, et al. Helicobacter pylori infection downregulates the DNA glycosylase NEIL2, resulting in increased genome damage and inflammation in gastric epithelial cells. J Biol Chem. 2020; 295(32): 11082‐ 98. 32518160 PMC7415988
  12. [17]Sierra JC, Asim M, Verriere TG, Piazuelo MB, Suarez G, Romero‐Gallo J, et al. Epidermal growth factor receptor inhibition downregulates Helicobacter pylori‐induced epithelial inflammatory responses, DNA damage and gastric carcinogenesis. Gut. 2018; 67(7): 1247‐ 1260. 28473630 PMC5671361
  13. [18]Xie C, Li N, Wang H, He C, Hu Y, Peng C, et al. Inhibition of autophagy aggravates DNA damage response and gastric tumorigenesis via Rad51 ubiquitination in response to H. pylori infection. Gut Microbes. 2020; 11(6): 1567‐ 1589. 32588736 PMC7524160
  14. [19]Han T, Jing X, Bao J, Zhao L, Zhang A, Miao R, et al. H. pylori infection alters repair of DNA double‐strand breaks via SNHG17. J Clin Invest. 2020; 130(7): 3901‐ 18. 32538894 PMC7324211
  15. [20]Zhang G, Xu Y, Wang S, Gong Z, Zou C, Zhang H, et al. LncRNA SNHG17 promotes gastric cancer progression by epigenetically silencing of p15 and p57. J Cell Physiol. 2019; 234(4): 5163‐ 74. 30256413
  16. [21]Tegtmeyer N, Wessler S, Necchi V, Rohde M, Harrer A, Rau TT, et al. Helicobacter pylori Employs a Unique Basolateral Type IV Secretion Mechanism for CagA Delivery. Cell Host Microbe. 2017; 22(4): 552‐ 60.e5. 29024645
  17. [22]Matson V, Chervin CS, Gajewski TF. Cancer and the Microbiome: Influence of the Commensal Microbiota on Cancer, Immune Responses, and Immunotherapy. Gastroenterology. 2021; 160(2): 600– 613. 33253684 PMC8409239
  18. [23]Brennan CA, Garrett WS. Fusobacterium nucleatum ‐ symbiont, opportunist and oncobacterium. Nat Rev Microbiol. 2019; 17(3): 156‐ 66. 30546113 PMC6589823
  19. [24]Leung A, Tsoi H, Yu J. Fusobacterium and Escherichia: models of colorectal cancer driven by microbiota and the utility of microbiota in colorectal cancer screening. Expert Rev Gastroenterol Hepatol. 2015; 9(5): 651‐ 7. 25582922
  20. [25]Hashemi Goradel N, Heidarzadeh S, Jahangiri S, Farhood B, Mortezaee K, Khanlarkhani N, et al. Fusobacterium nucleatum and colorectal cancer: A mechanistic overview. J Cell Physiol. 2019; 234(3): 2337‐ 44. 30191984
  21. [27]Gholizadeh P, Eslami H, Kafil HS. Carcinogenesis mechanisms of Fusobacterium nucleatum. Biomed Pharmacother. 2017; 89: 918‐ 25. 28292019
  22. [28]Mima K, Sukawa Y, Nishihara R, Qian ZR, Yamauchi M, Inamura K, et al. Fusobacterium nucleatum and T Cells in Colorectal Carcinoma. JAMA Oncol. 2015; 1(5): 653‐ 61. 26181352 PMC4537376
  23. [29]Yang Y, Weng W, Peng J, Hong L, Yang L, Toiyama Y, et al. Fusobacterium nucleatum Increases Proliferation of Colorectal Cancer Cells and Tumor Development in Mice by Activating Toll‐Like Receptor 4 Signaling to Nuclear Factor‐κB, and Up‐regulating Expression of MicroRNA‐21. Gastroenterology. 2017; 152(4): 851‐ 866.e24. 27876571 PMC5555435
  24. [30]Yu T, Guo F, Yu Y, Sun T, Ma D, Han J, et al. Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy. Cell. 2017; 170(3): 548‐ 63.e16. 28753429 PMC5767127
  25. [31]Chen S, Su T, Zhang Y, Lee A, He J, Ge Q, et al. Fusobacterium nucleatum promotes colorectal cancer metastasis by modulating KRT7‐AS/KRT7. Gut Microbes. 2020; 11(3): 511‐ 525. 31910722 PMC7524269
  26. [32]Guo S, Chen J, Chen F, Zeng Q, Liu WL, Zhang G. Exosomes derived from Fusobacterium nucleatum‐infected colorectal cancer cells facilitate tumour metastasis by selectively carrying miR‐1246/92b‐3p/27a‐3p and CXCL16. Gut. 2020. 33172926
  27. [33]Hong J, Guo F, Lu SY, Shen C, Ma D, Zhang X, et al. F. nucleatum targets lncRNA ENO1‐IT1 to promote glycolysis and oncogenesis in colorectal cancer. Gut. 2020. 33318144
  28. [34]Aymeric L, Donnadieu F, Mulet C, du Merle L, Nigro G, Saffarian A, et al. Colorectal cancer specific conditions promote Streptococcus gallolyticus gut colonization. Proc Natl Acad Sci U S A. 2018; 115(2): E283‐ E291. 29279402 PMC5777054
  29. [36]Rackaityte E, Lynch SV. The human microbiome in the 21(st) century. Nat Commun. 2020; 11(1): 5256. 33067429 PMC7567807
  30. [37]Wong SH, Zhao L, Zhang X, Nakatsu G, Han J, Xu W, et al. Gavage of Fecal Samples From Patients With Colorectal Cancer Promotes Intestinal Carcinogenesis in Germ‐Free and Conventional Mice. Gastroenterology. 2017; 153(6): 1621‐ 1633.e6. 28823860
  31. [38]Ansari I, Raddatz G, Gutekunst J, Ridnik M, Cohen D, Abu‐Remaileh M, et al. The microbiota programs DNA methylation to control intestinal homeostasis and inflammation. Nat Microbiol. 2020; 5(4): 610‐ 9. 32015497
  32. [41]Belkaid Y, Harrison OJ. Homeostatic Immunity and the Microbiota. Immunity. 2017; 46(4): 562‐ 76. 28423337 PMC5604871
  33. [42]Michaudel C, Sokol H. The Gut Microbiota at the Service of Immunometabolism. Cell Metab. 2020; 32(4): 514‐ 23. 32946809
  34. [43]Schulthess J, Pandey S, Capitani M, Rue‐Albrecht KC, Arnold I, Franchini F, et al. The Short Chain Fatty Acid Butyrate Imprints an Antimicrobial Program in Macrophages. Immunity. 2019; 50(2): 432‐45 e7. 30683619 PMC6382411
  35. [45]Gao J, Xu K, Liu H, Liu G, Bai M, Peng C, et al. Impact of the Gut Microbiota on Intestinal Immunity Mediated by Tryptophan Metabolism. Front Cell Infect Microbiol. 2018; 8: 13. 29468141 PMC5808205
  36. [46]Kumar H, Kawai T, Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol. 2011; 30(1): 16‐ 34. 21235323
  37. [47]Blander JM, Longman RS, Iliev ID, Sonnenberg GF, Artis D. Regulation of inflammation by microbiota interactions with the host. Nat Immunol. 2017; 18(8): 851‐ 60. 28722709 PMC5800875
  38. [48]Schirmer M, Smeekens SP, Vlamakis H, Jaeger M, Oosting M, Franzosa EA, et al. Linking the Human Gut Microbiome to Inflammatory Cytokine Production Capacity. Cell. 2016; 167(4): 1125‐ 36.e8. 27814509 PMC5131922
  39. [49]Bellone M, Brevi A, Huber S. Microbiota‐Propelled T Helper 17 Cells in Inflammatory Diseases and Cancer. Microbiol Mol Biol Rev. 2020; 84(2). PMC7062199 32132244
  40. [50]Jin C, Lagoudas GK, Zhao C, Bullman S, Bhutkar A, Hu B, et al. Commensal Microbiota Promote Lung Cancer Development via γδ T Cells. Cell. 2019; 176(5): 998‐ 1013.e16. 30712876 PMC6691977
  41. [51]Schroeder BO. Fight them or feed them: how the intestinal mucus layer manages the gut microbiota. Gastroenterol Rep (Oxf). 2019; 7(1): 3‐ 12. 30792861 PMC6375348
  42. [52]Belzer C, Chia LW, Aalvink S, Chamlagain B, Piironen V, Knol J, et al. Microbial Metabolic Networks at the Mucus Layer Lead to Diet‐Independent Butyrate and Vitamin B(12) Production by Intestinal Symbionts. mBio. 2017; 8(5). PMC5605934 28928206
  43. [54]Schroeder BO, Birchenough GMH, Stahlman M, Arike L, Johansson MEV, Hansson GC, et al. Bifidobacteria or Fiber Protects against Diet‐Induced Microbiota‐Mediated Colonic Mucus Deterioration. Cell Host Microbe. 2018; 23(1): 27‐40 e7. 29276171 PMC5764785
  44. [55]Desai MS, Seekatz AM, Koropatkin NM, Kamada N, Hickey CA, Wolter M, et al. A Dietary Fiber‐Deprived Gut Microbiota Degrades the Colonic Mucus Barrier and Enhances Pathogen Susceptibility. Cell. 2016; 167(5): 1339‐ 53.e21. 27863247 PMC5131798
  45. [56]Lee MH, Lozano G. Regulation of the p53‐MDM2 pathway by 14‐3‐3 sigma and other proteins. Semin Cancer Biol. 2006; 16(3): 225‐ 34. 16697215
  46. [57]Yang HY, Wen YY, Chen CH, Lozano G, Lee MH. 14‐3‐3 sigma positively regulates p53 and suppresses tumor growth. Mol Cell Biol. 2003; 23(20): 7096‐ 107. 14517281 PMC230310
  47. [59]Lau HCH, Yu J. Gut microbiome alters functions of mutant p53 to promote tumorigenesis. Signal Transduct Target Ther. 2020; 5(1): 232. 33037184 PMC7547703
  48. [60]Elinav E, Garrett WS, Trinchieri G, Wargo J. The cancer microbiome. Nat Rev Cancer. 2019; 19(7): 371‐ 6. 31186547 PMC6700740
  49. [61]Schroeder BO, Backhed F. Signals from the gut microbiota to distant organs in physiology and disease. Nat Med. 2016; 22(10): 1079‐ 89. 27711063
  50. [62]Krautkramer KA, Fan J, Bäckhed F. Gut microbial metabolites as multi‐kingdom intermediates. Nat Rev Microbiol. 2020. 32968241
  51. [63]Rooks MG, Garrett WS. Gut microbiota, metabolites and host immunity. Nat Rev Immunol. 2016; 16(6): 341‐ 52. 27231050 PMC5541232
  52. [64]Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol. 2014; 12(10): 661‐ 72. 25198138
  53. [65]Ridlon JM, Devendran S, Alves JM, Doden H, Wolf PG, Pereira GV, et al. The ‘in vivo lifestyle’ of bile acid 7α‐dehydroxylating bacteria: comparative genomics, metatranscriptomic, and bile acid metabolomics analysis of a defined microbial community in gnotobiotic mice. Gut Microbes. 2020; 11(3): 381‐ 404. 31177942 PMC7524365
  54. [66]Ridlon JM, Wolf PG, Gaskins HR. Taurocholic acid metabolism by gut microbes and colon cancer. Gut Microbes. 2016; 7(3): 201‐ 15. 27003186 PMC4939921
  55. [68]Fu T, Coulter S, Yoshihara E, Oh TG, Fang S, Cayabyab F, et al. FXR Regulates Intestinal Cancer Stem Cell Proliferation. Cell. 2019; 176(5): 1098‐112 e18. 30794774 PMC6701863
  56. [69]Hang S, Paik D, Yao L, Kim E, Trinath J, Lu J, et al. Bile acid metabolites control T(H)17 and T(reg) cell differentiation. Nature. 2019; 576(7785): 143‐ 148. 31776512 PMC6949019
  57. [70]Song X, Sun X, Oh SF, Wu M, Zhang Y, Zheng W, et al. Microbial bile acid metabolites modulate gut RORγ(+) regulatory T cell homeostasis. Nature. 2020; 577(7790): 410‐ 415. 31875848 PMC7274525
  58. [71]Lin R, Zhan M, Yang L, Wang H, Shen H, Huang S, et al. Deoxycholic acid modulates the progression of gallbladder cancer through N(6)‐methyladenosine‐dependent microRNA maturation. Oncogene. 2020; 39(26): 4983‐ 5000. 32514152 PMC7314665
  59. [73]Xu R, Wang Q, Li L. A genome‐wide systems analysis reveals strong link between colorectal cancer and trimethylamine N‐oxide (TMAO), a gut microbial metabolite of dietary meat and fat. BMC Genomics. 2015; 16(7): S4. PMC4474417 26100814
  60. [74]Wang Z, Roberts AB, Buffa JA, Levison BS, Zhu W, Org E, et al. Non‐lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis. Cell. 2015; 163(7): 1585‐ 95. 26687352 PMC4871610
  61. [75]Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, et al. Intestinal microbiota metabolism of L‐carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013; 19(5): 576‐ 85. 23563705 PMC3650111
  62. [76]Gao Q, Wang Y, Wang X, Fu S, Zhang X, Wang RT, et al. Decreased levels of circulating trimethylamine N‐oxide alleviate cognitive and pathological deterioration in transgenic mice: a potential therapeutic approach for Alzheimer's disease. Aging (Albany NY). 2019; 11(19): 8642‐ 63. 31612864 PMC6814608
  63. [77]Chan CWH, Law BMH, Waye MMY, Chan JYW, So WKW, Chow KM. Trimethylamine‐N‐oxide as One Hypothetical Link for the Relationship between Intestinal Microbiota and Cancer ‐ Where We Are and Where Shall We Go? J Cancer. 2019; 10(23): 5874‐ 82. 31737123 PMC6843879
  64. [79]Venkateswaran N, Lafita‐Navarro MC, Hao YH, Kilgore JA, Perez‐Castro L, Braverman J, et al. MYC promotes tryptophan uptake and metabolism by the kynurenine pathway in colon cancer. Genes Dev. 2019; 33(17‐18): 1236‐ 51. 31416966 PMC6719621
  65. [81]Wu H, Tremaroli V, Schmidt C, Lundqvist A, Olsson LM, Krämer M, et al. The Gut Microbiota in Prediabetes and Diabetes: A Population‐Based Cross‐Sectional Study. Cell Metab. 2020; 32(3): 379‐ 90.e3. 32652044
  66. [82]Forslund K, Hildebrand F, Nielsen T, Falony G, Le Chatelier E, Sunagawa S, et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. 2015; 528(7581): 262‐ 6. 26633628 PMC4681099
  67. [83]Koh A, Molinaro A, Ståhlman M, Khan MT, Schmidt C, Mannerås‐Holm L, et al. Microbially Produced Imidazole Propionate Impairs Insulin Signaling through mTORC1. Cell. 2018; 175(4): 947‐ 61.e17. 30401435
  68. [84]Molinaro A, Bel Lassen P, Henricsson M, Wu H, Adriouch S, Belda E, et al. Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecology. Nat Commun. 2020; 11(1): 5881. 33208748 PMC7676231
  69. [85]Koh A, Mannerås‐Holm L, Yunn NO, Nilsson PM, Ryu SH, Molinaro A, et al. Microbial Imidazole Propionate Affects Responses to Metformin through p38γ‐Dependent Inhibitory AMPK Phosphorylation. Cell Metab. 2020; 32(4): 643‐ 653.e4. 32783890 PMC7546034
  70. [86]Velazquez‐Torres G, Fuentes‐Mattei E, Choi HH, Yeung SJ, Meng X, Lee MH. Diabetes mellitus type 2 drives metabolic reprogramming to promote pancreatic cancer growth. Gastroenterol Rep (Oxf). 2020; 8(4): 261‐ 76. 32843973 PMC7434590
  71. [87]Fuentes‐Mattei E, Velazquez‐Torres G, Phan L, Zhang F, Chou PC, Shin JH, et al. Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor‐positive breast cancer. J Natl Cancer Inst. 2014; 106(7). PMC4110474 24957076
  72. [88]He X, Esteva FJ, Ensor J, Hortobagyi GN, Lee MH, Yeung SC. Metformin and thiazolidinediones are associated with improved breast cancer‐specific survival of diabetic women with HER2+ breast cancer. Ann Oncol. 2012; 23(7): 1771‐ 80. 22112968 PMC3387820
  73. [89]He XX, Tu SM, Lee MH, Yeung SC. Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Ann Oncol. 2011; 22(12): 2640‐ 5. 21415239 PMC3221513
  74. [91]Peterson CT, Rodionov DA, Osterman AL, Peterson SN. B Vitamins and Their Role in Immune Regulation and Cancer. Nutrients. 2020; 12(11). PMC7693142 33158037
  75. [92]Thangaraju M, Cresci GA, Liu K, Ananth S, Gnanaprakasam JP, Browning DD, et al. GPR109A is a G‐protein‐coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon. Cancer Res. 2009; 69(7): 2826‐ 32. 19276343 PMC3747834
  76. [93]Singh N, Gurav A, Sivaprakasam S, Brady E, Padia R, Shi H, et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity. 2014; 40(1): 128‐ 39. 24412617 PMC4305274
  77. [94]Li J, Kong D, Wang Q, Wu W, Tang Y, Bai T, et al. Niacin ameliorates ulcerative colitis via prostaglandin D(2)‐mediated D prostanoid receptor 1 activation. EMBO Mol Med. 2017; 9(5): 571‐ 588. 28341703 PMC5412792
  78. [95]Li K, Wu JL, Qin B, Fan Z, Tang Q, Lu W, et al. ILF3 is a substrate of SPOP for regulating serine biosynthesis in colorectal cancer. Cell Res. 2020; 30(2): 163‐ 78. 31772275 PMC7015059
  79. [96]Choi HH, Zou S, Wu JL, Wang H, Phan L, Li K, et al. EGF Relays Signals to COP1 and Facilitates FOXO4 Degradation to Promote Tumorigenesis. Adv Sci (Weinh). 2020; 7(20): 2000681. 33101846 PMC7578864
  80. [97]Hosseinkhani F, Heinken A, Thiele I, Lindenburg PW, Harms AC, Hankemeier T. The contribution of gut bacterial metabolites in the human immune signaling pathway of non‐communicable diseases. Gut Microbes. 2021; 13(1): 1‐ 22. PMC7899087 33590776
  81. [98]Li J, Meng Y, Wu X, Sun Y. Polyamines and related signaling pathways in cancer. Cancer Cell Int. 2020; 20(1): 539. 33292222 PMC7643453
  82. [99]Li L, Mao Y, Zhao L, Li L, Wu J, Zhao M, et al. p53 regulation of ammonia metabolism through urea cycle controls polyamine biosynthesis. Nature. 2019; 567(7747): 253‐ 6. 30842655
  83. [100]Johnson CH, Dejea CM, Edler D, Hoang LT, Santidrian AF, Felding BH, et al. Metabolism links bacterial biofilms and colon carcinogenesis. Cell Metab. 2015; 21(6): 891‐ 7. 25959674 PMC4456201
  84. [101]Selma MV, Beltran D, Luna MC, Romo‐Vaquero M, Garcia‐Villalba R, Mira A, et al. Isolation of Human Intestinal Bacteria Capable of Producing the Bioactive Metabolite Isourolithin A from Ellagic Acid. Front Microbiol. 2017; 8: 1521. 28824607 PMC5545574
  85. [102]Singh R, Chandrashekharappa S, Bodduluri SR, Baby BV, Hegde B, Kotla NG, et al. Enhancement of the gut barrier integrity by a microbial metabolite through the Nrf2 pathway. Nat Commun. 2019; 10(1): 89. 30626868 PMC6327034
  86. [106]Zitvogel L, Daillère R, Roberti MP, Routy B, Kroemer G. Anticancer effects of the microbiome and its products. Nat Rev Microbiol. 2017; 15(8): 465‐ 78. 28529325
  87. [107]Plaza‐Diaz J, Ruiz‐Ojeda FJ, Gil‐Campos M, Gil A. Mechanisms of Action of Probiotics. Adv Nutr. 2019; 10(1): S49‐ s66. 30721959 PMC6363529
  88. [108]Motevaseli E, Dianatpour A, Ghafouri‐Fard S. The Role of Probiotics in Cancer Treatment: Emphasis on their In Vivo and In Vitro Anti‐metastatic Effects. Int J Mol Cell Med. 2017; 6(2): 66‐ 76. 28890883 PMC5581548
  89. [110]Wei D, Heus P, van de Wetering FT, van Tienhoven G, Verleye L, Scholten RJ. Probiotics for the prevention or treatment of chemotherapy‐ or radiotherapy‐related diarrhoea in people with cancer. Cochrane Database Syst Rev. 2018; 8(8): Cd008831. 30168576 PMC6513393
  90. [111]Tarrah A, de Castilhos J, Rossi RC, Duarte VDS, Ziegler DR, Corich V, et al. In vitro Probiotic Potential and Anti‐cancer Activity of Newly Isolated Folate‐Producing Streptococcus thermophilus Strains. Front Microbiol. 2018; 9: 2214. 30283428 PMC6156529
  91. [112]Sanders ME, Merenstein DJ, Reid G, Gibson GR, Rastall RA. Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. Nat Rev Gastroenterol Hepatol. 2019; 16(10): 605‐ 16. 31296969
  92. [114]La Rosa SL, Leth ML, Michalak L, Hansen ME, Pudlo NA, Glowacki R, et al. The human gut Firmicute Roseburia intestinalis is a primary degrader of dietary β‐mannans. Nat Commun. 2019; 10(1): 905. 30796211 PMC6385246
  93. [115]Ansaldo E, Slayden LC, Ching KL, Koch MA, Wolf NK, Plichta DR, et al. Akkermansia muciniphila induces intestinal adaptive immune responses during homeostasis. Science. 2019; 364(6446): 1179‐ 1184. 31221858 PMC6645389
  94. [118]Xie C, Coda R, Chamlagain B, Varmanen P, Piironen V, Katina K. Co‐fermentation of Propionibacterium freudenreichii and Lactobacillus brevis in Wheat Bran for in situ Production of Vitamin B12. Front Microbiol. 2019; 10: 1541. 31333632 PMC6624789
  95. [119]Yeom J, Ma S, Lim YH. Probiotic Propionibacterium freudenreichii MJ2 Enhances Osteoblast Differentiation and Mineralization by Increasing the OPG/RANKL Ratio. Microorganisms. 2021; 9(4). PMC8064112 33805153
  96. [120]Chou YC, Ho PY, Chen WJ, Wu SH, Pan MH. Lactobacillus fermentum V3 ameliorates colitis‐associated tumorigenesis by modulating the gut microbiome. Am J Cancer Res. 2020; 10(4): 1170‐ 81. 32368393 PMC7191089
  97. [121]Wu H, Xie S, Miao J, Li Y, Wang Z, Wang M, et al. Lactobacillus reuteri maintains intestinal epithelial regeneration and repairs damaged intestinal mucosa. Gut Microbes. 2020; 11(4): 997‐ 1014. 32138622 PMC7524370
  98. [122]Cervantes‐Barragan L, Chai JN, Tianero MD, Di Luccia B, Ahern PP, Merriman J, et al. Lactobacillus reuteri induces gut intraepithelial CD4(+)CD8αα(+) T cells. Science. 2017; 357(6353): 806‐ 810. 28775213 PMC5687812
  99. [123]Sivan A, Corrales L, Hubert N, Williams JB, Aquino‐Michaels K, Earley ZM, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti‐PD‐L1 efficacy. Science. 2015; 350(6264): 1084‐ 9. 26541606 PMC4873287
  100. [124]Schroeder BO, Birchenough GMH, Ståhlman M, Arike L, Johansson MEV, Hansson GC, et al. Bifidobacteria or Fiber Protects against Diet‐Induced Microbiota‐Mediated Colonic Mucus Deterioration. Cell Host Microbe. 2018; 23(1): 27‐ 40.e7. 29276171 PMC5764785
  101. [126]Zagato E, Pozzi C, Bertocchi A, Schioppa T, Saccheri F, Guglietta S, et al. Endogenous murine microbiota member Faecalibaculum rodentium and its human homologue protect from intestinal tumour growth. Nat Microbiol. 2020; 5(3): 511‐ 24. 31988379 PMC7048616
  102. [127]Li Q, Hu W, Liu WX, Zhao LY, Huang D, Liu XD, et al. Streptococcus thermophilus Inhibits Colorectal Tumorigenesis Through Secreting β‐Galactosidase. Gastroenterology. 2021; 160(4): 1179‐ 1193. 32920015
  103. [128]Konings EJ, Roomans HH, Dorant E, Goldbohm RA, Saris WH, van den Brandt PA. Folate intake of the Dutch population according to newly established liquid chromatography data for foods. Am J Clin Nutr. 2001; 73(4): 765‐ 76. 11273852
  104. [129]Wasilewska E, Zlotkowska D, Wroblewska B. Yogurt starter cultures of Streptococcus thermophilus and Lactobacillus bulgaricus ameliorate symptoms and modulate the immune response in a mouse model of dextran sulfate sodium‐induced colitis. J Dairy Sci. 2019; 102(1): 37‐ 53. 30343915
  105. [130]Chen F, Stappenbeck TS. Microbiome control of innate reactivity. Curr Opin Immunol. 2019; 56: 107‐ 13. 30677624
  106. [131]Jain T, Sharma P, Are AC, Vickers SM, Dudeja V. New Insights Into the Cancer‐Microbiome‐Immune Axis: Decrypting a Decade of Discoveries. Front Immunol. 2021; 12: 622064. 33708214 PMC7940198
  107. [132]Tanoue T, Morita S, Plichta DR, Skelly AN, Suda W, Sugiura Y, et al. A defined commensal consortium elicits CD8 T cells and anti‐cancer immunity. Nature. 2019; 565(7741): 600‐ 5. 30675064
  108. [133]Arpaia N, Campbell C, Fan X, Dikiy S, van der Veeken J, deRoos P, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T‐cell generation. Nature. 2013; 504(7480): 451‐ 5. 24226773 PMC3869884
  109. [134]Xing C, Wang M, Ajibade AA, Tan P, Fu C, Chen L, et al. Microbiota regulate innate immune signaling and protective immunity against cancer. Cell Host Microbe. 2021. PMC8192480 33894128
  110. [135]Trompette A, Gollwitzer ES, Yadava K, Sichelstiel AK, Sprenger N, Ngom‐Bru C, et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat Med. 2014; 20(2): 159‐ 66. 24390308
  111. [136]Lupton JR. Microbial degradation products influence colon cancer risk: the butyrate controversy. J Nutr. 2004; 134(2): 479‐ 82. 14747692
  112. [137]Schulthess J, Pandey S, Capitani M, Rue‐Albrecht KC, Arnold I, Franchini F, et al. The Short Chain Fatty Acid Butyrate Imprints an Antimicrobial Program in Macrophages. Immunity. 2019; 50(2): 432‐ 45.e7. 30683619 PMC6382411
  113. [138]van den Berg FF, van Dalen D, Hyoju SK, van Santvoort HC, Besselink MG, Wiersinga WJ, et al. Western‐type diet influences mortality from necrotising pancreatitis and demonstrates a central role for butyrate. Gut. 2021; 70(5): 915– 927. 32873697 PMC7917160
  114. [139]Zierer J, Jackson MA, Kastenmüller G, Mangino M, Long T, Telenti A, et al. The fecal metabolome as a functional readout of the gut microbiome. Nat Genet. 2018; 50(6): 790‐ 5. 29808030 PMC6104805
  115. [140]Rajpoot M, Sharma AK, Sharma A, Gupta GK. Understanding the microbiome: Emerging biomarkers for exploiting the microbiota for personalized medicine against cancer. Semin Cancer Biol. 2018; 52(Pt 1): 1‐ 8. 29425888
  116. [141]Hamada T, Nowak JA, Milner DA, Jr., Song M, Ogino S. Integration of microbiology, molecular pathology, and epidemiology: a new paradigm to explore the pathogenesis of microbiome‐driven neoplasms. J Pathol. 2019; 247(5): 615‐ 28. 30632609 PMC6509405
  117. [142]Sears CL, Garrett WS. Microbes, microbiota, and colon cancer. Cell Host Microbe. 2014; 15(3): 317‐ 28. 24629338 PMC4003880
  118. [143]Wong SH, Yu J. Gut microbiota in colorectal cancer: mechanisms of action and clinical applications. Nat Rev Gastroenterol Hepatol. 2019; 16(11): 690‐ 704. 31554963
  119. [144]Yang J, Yu J. The association of diet, gut microbiota and colorectal cancer: what we eat may imply what we get. Protein Cell. 2018; 9(5): 474‐ 87. 29713943 PMC5960467
  120. [145]Feng Q, Liang S, Jia H, Stadlmayr A, Tang L, Lan Z, et al. Gut microbiome development along the colorectal adenoma‐carcinoma sequence. Nat Commun. 2015; 6: 6528. 25758642
  121. [146]Kostic AD, Chun E, Robertson L, Glickman JN, Gallini CA, Michaud M, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor‐immune microenvironment. Cell Host Microbe. 2013; 14(2): 207‐ 15. 23954159 PMC3772512
  122. [147]Zackular JP, Rogers MA, Ruffin MTt, Schloss PD. The human gut microbiome as a screening tool for colorectal cancer. Cancer Prev Res (Phila). 2014; 7(11): 1112‐ 21. 25104642 PMC4221363
  123. [149]Peek RM, Jr., Crabtree JE. Helicobacter infection and gastric neoplasia. J Pathol. 2006; 208(2): 233‐ 48. 16362989
  124. [150]Coker OO, Dai Z, Nie Y, Zhao G, Cao L, Nakatsu G, et al. Mucosal microbiome dysbiosis in gastric carcinogenesis. Gut. 2018; 67(6): 1024‐ 32. 28765474 PMC5969346
  125. [152]Di Pilato V, Freschi G, Ringressi MN, Pallecchi L, Rossolini GM, Bechi P. The esophageal microbiota in health and disease. Ann N Y Acad Sci. 2016; 1381(1): 21‐ 33. 27415419
  126. [153]Baba Y, Iwatsuki M, Yoshida N, Watanabe M, Baba H. Review of the gut microbiome and esophageal cancer: Pathogenesis and potential clinical implications. Ann Gastroenterol Surg. 2017; 1(2): 99‐ 104. 29863142 PMC5881342
  127. [154]Nardone G, Compare D, Rocco A. A microbiota‐centric view of diseases of the upper gastrointestinal tract. Lancet Gastroenterol Hepatol. 2017; 2(4): 298‐ 312. 28404159
  128. [155]Yang W, Chen C‐H, Jia M, Xing X, Gao L, Tsai H‐T, et al. Tumor‐Associated Microbiota in Esophageal Squamous Cell Carcinoma. Frontiers in Cell and Developmental Biology. 2021; 9: 249. PMC7930383 33681225
  129. [156]Chen X, Yuan Z, Lu M, Zhang Y, Jin L, Ye W. Poor oral health is associated with an increased risk of esophageal squamous cell carcinoma ‐ a population‐based case‐control study in China. Int J Cancer. 2017; 140(3): 626‐ 35. 27778330
  130. [157]Yamamura K, Izumi D, Kandimalla R, Sonohara F, Baba Y, Yoshida N, et al. Intratumoral Fusobacterium Nucleatum Levels Predict Therapeutic Response to Neoadjuvant Chemotherapy in Esophageal Squamous Cell Carcinoma. Clin Cancer Res. 2019; 25(20): 6170‐ 6179. 31358543 PMC6801075
  131. [158]Malinowski B, Węsierska A, Zalewska K, Sokołowska MM, Bursiewicz W, Socha M, et al. The role of Tannerella forsythia and Porphyromonas gingivalis in pathogenesis of esophageal cancer. Infect Agent Cancer. 2019; 14: 3. 30728854 PMC6352356
  132. [159]Tan W, Liao TH, Wang J, Ye Y, Wei YC, Zhou HK, et al. A recently evolved diflavin‐containing monomeric nitrate reductase is responsible for highly efficient bacterial nitrate assimilation. J Biol Chem. 2020; 295(15): 5051‐ 66. 32111737 PMC7152768
  133. [160]Wang Z, Gao X, Zeng R, Wu Q, Sun H, Wu W, et al. Changes of the Gastric Mucosal Microbiome Associated With Histological Stages of Gastric Carcinogenesis. Front Microbiol. 2020; 11: 997. 32547510 PMC7272699
  134. [161]Yang L, Francois F, Pei Z. Molecular pathways: pathogenesis and clinical implications of microbiome alteration in esophagitis and Barrett esophagus. Clin Cancer Res. 2012; 18(8): 2138‐ 44. 22344232 PMC3725293
  135. [162]Zhang G, Meredith TC, Kahne D. On the essentiality of lipopolysaccharide to Gram‐negative bacteria. Curr Opin Microbiol. 2013; 16(6): 779‐ 85. 24148302 PMC3974409
  136. [163]Pushalkar S, Hundeyin M, Daley D, Zambirinis CP, Kurz E, Mishra A, et al. The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression. Cancer Discov. 2018; 8(4): 403‐ 16. 29567829 PMC6225783
  137. [164]Fan X, Alekseyenko AV, Wu J, Peters BA, Jacobs EJ, Gapstur SM, et al. Human oral microbiome and prospective risk for pancreatic cancer: a population‐based nested case‐control study. Gut. 2018; 67(1): 120‐ 7. 27742762 PMC5607064
  138. [166]McAllister F, Khan MAW, Helmink B, Wargo JA. The Tumor Microbiome in Pancreatic Cancer: Bacteria and Beyond. Cancer Cell. 2019; 36(6): 577‐ 9. 31951558
  139. [167]Kiss B, Mikó E, Sebő É, Toth J, Ujlaki G, Szabó J, et al. Oncobiosis and Microbial Metabolite Signaling in Pancreatic Adenocarcinoma. Cancers (Basel). 2020; 12(5). PMC7281526 32344895
  140. [168]Aykut B, Pushalkar S, Chen R, Li Q, Abengozar R, Kim JI, et al. The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL. Nature. 2019; 574(7777): 264‐ 7. 31578522 PMC6858566
  141. [169]Farrell JJ, Zhang L, Zhou H, Chia D, Elashoff D, Akin D, et al. Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. Gut. 2012; 61(4): 582‐ 8. 21994333 PMC3705763
  142. [170]Ingman WV. The Gut Microbiome: A New Player in Breast Cancer Metastasis. Cancer Res. 2019; 79(14): 3539‐ 41. 31308136
  143. [171]Chen J, Douglass J, Prasath V, Neace M, Atrchian S, Manjili MH, et al. The microbiome and breast cancer: a review. Breast Cancer Res Treat. 2019; 178(3): 493‐ 6. 31456069
  144. [172]Buchta Rosean C, Bostic RR, Ferey JCM, Feng TY, Azar FN, Tung KS, et al. Preexisting Commensal Dysbiosis Is a Host‐Intrinsic Regulator of Tissue Inflammation and Tumor Cell Dissemination in Hormone Receptor‐Positive Breast Cancer. Cancer Res. 2019; 79(14): 3662‐ 75. 31064848 PMC6983951
  145. [174]Puglisi R, Bellenghi M, Pontecorvi G, Pallante G, Carè A, Mattia G. Biomarkers for Diagnosis, Prognosis and Response to Immunotherapy in Melanoma. Cancers (Basel). 2021; 13(12). PMC8228007 34207514
  146. [175]Limeta A, Ji B, Levin M, Gatto F, Nielsen J. Meta‐analysis of the gut microbiota in predicting response to cancer immunotherapy in metastatic melanoma. JCI Insight. 2020; 5(23). PMC7714408 33268597
  147. [176]Tomela K, Pietrzak B, Schmidt M, Mackiewicz A. The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients. Life (Basel). 2020; 10(10). PMC7600343 32992737
  148. [177]Zhou A, Tang L, Zeng S, Lei Y, Yang S, Tang B. Gut microbiota: A new piece in understanding hepatocarcinogenesis. Cancer Lett. 2020; 474: 15‐ 22. 31917160
  149. [179]Qin N, Yang F, Li A, Prifti E, Chen Y, Shao L, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature. 2014; 513(7516): 59‐ 64. 25079328
  150. [180]Zhang Q, Ma C, Duan Y, Heinrich B, Rosato U, Diggs LP, et al. Gut microbiome directs hepatocytes to recruit MDSC and promote cholangiocarcinoma. Cancer Discov. 2021; 11(5): 1248– 1267. 33323397 PMC8102309
  151. [181]Kolenbrander PE, Palmer RJ, Jr., Periasamy S, Jakubovics NS. Oral multispecies biofilm development and the key role of cell‐cell distance. Nat Rev Microbiol. 2010; 8(7): 471‐ 80. 20514044
  152. [183]Mao S, Park Y, Hasegawa Y, Tribble GD, James CE, Handfield M, et al. Intrinsic apoptotic pathways of gingival epithelial cells modulated by Porphyromonas gingivalis. Cell Microbiol. 2007; 9(8): 1997‐ 2007. 17419719 PMC2886729
  153. [184]Yilmaz O, Jungas T, Verbeke P, Ojcius DM. Activation of the phosphatidylinositol 3‐kinase/Akt pathway contributes to survival of primary epithelial cells infected with the periodontal pathogen Porphyromonas gingivalis. Infect Immun. 2004; 72(7): 3743‐ 51. 15213114 PMC427421
  154. [185]Maekawa T, Krauss JL, Abe T, Jotwani R, Triantafilou M, Triantafilou K, et al. Porphyromonas gingivalis manipulates complement and TLR signaling to uncouple bacterial clearance from inflammation and promote dysbiosis. Cell Host Microbe. 2014; 15(6): 768‐ 78. 24922578 PMC4071223
  155. [186]Liu S, Zhou X, Peng X, Li M, Ren B, Cheng G, et al. Porphyromonas gingivalis Promotes Immunoevasion of Oral Cancer by Protecting Cancer from Macrophage Attack. J Immunol. 2020; 205(1): 282‐ 9. 32471882
  156. [187]Chen Z, Wong PY, Ng CWK, Lan L, Fung S, Li JW, et al. The Intersection between Oral Microbiota, Host Gene Methylation and Patient Outcomes in Head and Neck Squamous Cell Carcinoma. Cancers (Basel). 2020; 12(11). PMC7698865 33218162
  157. [188]Swidsinski A, Dörffel Y, Loening‐Baucke V, Theissig F, Rückert JC, Ismail M, et al. Acute appendicitis is characterised by local invasion with Fusobacterium nucleatum/necrophorum. Gut. 2011; 60(1): 34‐ 40. 19926616
  158. [189]Strauss J, Kaplan GG, Beck PL, Rioux K, Panaccione R, Devinney R, et al. Invasive potential of gut mucosa‐derived Fusobacterium nucleatum positively correlates with IBD status of the host. Inflamm Bowel Dis. 2011; 17(9): 1971‐ 8. 21830275
  159. [191]Han YW, Houcken W, Loos BG, Schenkein HA, Tezal M. Periodontal disease, atherosclerosis, adverse pregnancy outcomes, and head‐and‐neck cancer. Adv Dent Res. 2014; 26(1): 47‐ 55. 24736704 PMC10477771
  160. [192]Ye C, Xia Z, Tang J, Khemwong T, Kapila Y, Kuraji R, et al. Unculturable and culturable periodontal‐related bacteria are associated with periodontal inflammation during pregnancy and with preterm low birth weight delivery. Sci Rep. 2020; 10(1): 15807. 32978483 PMC7519089
  161. [194]Dzutsev A, Badger JH, Perez‐Chanona E, Roy S, Salcedo R, Smith CK, et al. Microbes and Cancer. Annu Rev Immunol. 2017; 35: 199‐ 228. 28142322
  162. [195]Li Y, Luo ZY, Hu YY, Bi YW, Yang JM, Zou WJ, et al. The gut microbiota regulates autism‐like behavior by mediating vitamin B(6) homeostasis in EphB6‐deficient mice. Microbiome. 2020; 8(1): 120. 32819434 PMC7441571
  163. [196]Ma C, Han M, Heinrich B, Fu Q, Zhang Q, Sandhu M, et al. Gut microbiome‐mediated bile acid metabolism regulates liver cancer via NKT cells. Science. 2018; 360(6391). PMC6407885 29798856
  164. [198]Bergstrom K, Shan X, Casero D, Batushansky A, Lagishetty V, Jacobs JP, et al. Proximal colon‐derived O‐glycosylated mucus encapsulates and modulates the microbiota. Science. 2020; 370(6515): 467‐ 72. 33093110 PMC8132455
  165. [199]O'Donnell MP, Fox BW, Chao PH, Schroeder FC, Sengupta P. A neurotransmitter produced by gut bacteria modulates host sensory behaviour. Nature. 2020; 583(7816): 415‐ 20. 32555456 PMC7853625
  166. [200]Gil‐Cruz C, Perez‐Shibayama C, De Martin A, Ronchi F, van der Borght K, Niederer R, et al. Microbiota‐derived peptide mimics drive lethal inflammatory cardiomyopathy. Science. 2019; 366(6467): 881‐ 6. 31727837
  167. [201]Vicente‐Dueñas C, Janssen S, Oldenburg M, Auer F, González‐Herrero I, Casado‐García A, et al. An intact gut microbiome protects genetically predisposed mice against leukemia. Blood. 2020; 136(18): 2003‐ 17. 32911536 PMC7694022
  168. [202]Smith P, Willemsen D, Popkes M, Metge F, Gandiwa E, Reichard M, et al. Regulation of life span by the gut microbiota in the short‐lived African turquoise killifish. Elife. 2017; 6. PMC5566455 28826469
  169. [203]Schirmer M, Smeekens SP, Vlamakis H, Jaeger M, Oosting M, Franzosa EA, et al. Linking the Human Gut Microbiome to Inflammatory Cytokine Production Capacity. Cell. 2016; 167(7): 1897. 27984736
  170. [204]Guedj A, Volman Y, Geiger‐Maor A, Bolik J, Schumacher N, Künzel S, et al. Gut microbiota shape ‘inflamm‐ageing’ cytokines and account for age‐dependent decline in DNA damage repair. Gut. 2020; 69(6): 1064‐ 1075. 31586932
  171. [205]Parkar SG, Kalsbeek A, Cheeseman JF. Potential Role for the Gut Microbiota in Modulating Host Circadian Rhythms and Metabolic Health. Microorganisms. 2019; 7(2). PMC6406615 30709031
  172. [207]Wong‐Rolle A, Wei HK, Zhao C, Jin C. Unexpected guests in the tumor microenvironment: microbiome in cancer. Protein Cell. 2021; 12(5): 426– 435. 33296049 PMC8106554
  173. [209]Alexander JL, Wilson ID, Teare J, Marchesi JR, Nicholson JK, Kinross JM. Gut microbiota modulation of chemotherapy efficacy and toxicity. Nat Rev Gastroenterol Hepatol. 2017; 14(6): 356‐ 65. 28270698
  174. [210]Roy S, Trinchieri G. Microbiota: a key orchestrator of cancer therapy. Nat Rev Cancer. 2017; 17(5): 271‐ 85. 28303904
  175. [212]Kovatcheva‐Datchary P, Nilsson A, Akrami R, Lee YS, De Vadder F, Arora T, et al. Dietary Fiber‐Induced Improvement in Glucose Metabolism Is Associated with Increased Abundance of Prevotella. Cell Metab. 2015; 22(6): 971‐ 82. 26552345
  176. [216]Geller LT, Barzily‐Rokni M, Danino T, Jonas OH, Shental N, Nejman D, et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science. 2017; 357(6356): 1156‐ 60. 28912244 PMC5727343
  177. [217]Heshiki Y, Vazquez‐Uribe R, Li J, Ni Y, Quainoo S, Imamovic L, et al. Predictable modulation of cancer treatment outcomes by the gut microbiota. Microbiome. 2020; 8(1): 28. 32138779 PMC7059390
  178. [218]Chitapanarux I, Chitapanarux T, Traisathit P, Kudumpee S, Tharavichitkul E, Lorvidhaya V. Randomized controlled trial of live lactobacillus acidophilus plus bifidobacterium bifidum in prophylaxis of diarrhea during radiotherapy in cervical cancer patients. Radiat Oncol. 2010; 5: 31. 20444243 PMC2874795
  179. [219]Quigley EMM. Prebiotics and Probiotics in Digestive Health. Clin Gastroenterol Hepatol. 2019; 17(2): 333‐ 44. 30267869
  180. [220]Eslami M, Yousefi B, Kokhaei P, Hemati M, Nejad ZR, Arabkari V, et al. Importance of probiotics in the prevention and treatment of colorectal cancer. J Cell Physiol. 2019; 234(10): 17127‐ 43. 30912128
  181. [221]Marinelli L, Tenore GC, Novellino E. Probiotic species in the modulation of the anticancer immune response. Semin Cancer Biol. 2017; 46: 182‐ 90. 28844794
  182. [222]Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013; 342(6161): 967‐ 70. 24264989 PMC6709532
  183. [223]Ma W, Mao Q, Xia W, Dong G, Yu C, Jiang F. Gut Microbiota Shapes the Efficiency of Cancer Therapy. Front Microbiol. 2019; 10: 1050. 31293523 PMC6604670
  184. [224]Yeoh YK, Zuo T, Lui GC, Zhang F, Liu Q, Li AY, et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID‐19. Gut. 2021. PMC7804842 33431578
  185. [225]Hagan T, Cortese M, Rouphael N, Boudreau C, Linde C, Maddur MS, et al. Antibiotics‐Driven Gut Microbiome Perturbation Alters Immunity to Vaccines in Humans. Cell. 2019; 178(6): 1313‐ 28.e13. 31491384 PMC6750738
  186. [229]Elkrief A, Derosa L, Zitvogel L, Kroemer G, Routy B. The intimate relationship between gut microbiota and cancer immunotherapy. Gut Microbes. 2019; 10(3): 424‐ 8. 30339501 PMC6546322
  187. [231]McQuade JL, Daniel CR, Helmink BA, Wargo JA. Modulating the microbiome to improve therapeutic response in cancer. Lancet Oncol. 2019; 20(2): e77‐ e91. 30712808 PMC12908161
  188. [232]Nomura M, Nagatomo R, Doi K, Shimizu J, Baba K, Saito T, et al. Association of Short‐Chain Fatty Acids in the Gut Microbiome With Clinical Response to Treatment With Nivolumab or Pembrolizumab in Patients With Solid Cancer Tumors. JAMA Netw Open. 2020; 3(4): e202895. 32297948 PMC7163404
  189. [233]Azizian K, Pustokhina I, Ghanavati R, Hamblin MR, Amini A, Kouhsari E. The potential use of theranostic bacteria in cancer. J Cell Physiol. 2021; 236(6): 4184– 4194. 33174198
  190. [234]Longhi G, van Sinderen D, Ventura M, Turroni F. Microbiota and Cancer: The Emerging Beneficial Role of Bifidobacteria in Cancer Immunotherapy. Front Microbiol. 2020; 11: 575072. 33013813 PMC7507897
  191. [235]Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol. 2009; 9(5): 313‐ 23. 19343057 PMC4095778
  192. [236]Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014; 157(1): 121‐ 41. 24679531 PMC4056765
  193. [237]Todoric J, Antonucci L, Karin M. Targeting Inflammation in Cancer Prevention and Therapy. Cancer Prev Res (Phila). 2016; 9(12): 895‐ 905. 27913448 PMC5142754
  194. [238]Candela M, Turroni S, Biagi E, Carbonero F, Rampelli S, Fiorentini C, et al. Inflammation and colorectal cancer, when microbiota‐host mutualism breaks. World J Gastroenterol. 2014; 20(4): 908‐ 22. 24574765 PMC3921544
  195. [239]Zhang F, Luo W, Shi Y, Fan Z, Ji G. Should we standardize the 1,700‐year‐old fecal microbiota transplantation? Am J Gastroenterol. 2012; 107(11): 1755; author reply p.‐6. 23160295
  196. [240]Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery. 1958; 44(5): 854‐ 9. 13592638
  197. [241]Helmink BA, Khan MAW, Hermann A, Gopalakrishnan V, Wargo JA. The microbiome, cancer, and cancer therapy. Nat Med. 2019; 25(3): 377‐ 88. 30842679
  198. [243]Ooijevaar RE, Terveer EM, Verspaget HW, Kuijper EJ, Keller JJ. Clinical Application and Potential of Fecal Microbiota Transplantation. Annu Rev Med. 2019; 70: 335‐ 51. 30403550
  199. [244]Wang Z, Hua W, Li C, Chang H, Liu R, Ni Y, et al. Protective Role of Fecal Microbiota Transplantation on Colitis and Colitis‐Associated Colon Cancer in Mice Is Associated With Treg Cells. Front Microbiol. 2019; 10: 2498. 31798539 PMC6861520
  200. [245]Costello SP, Hughes PA, Waters O, Bryant RV, Vincent AD, Blatchford P, et al. Effect of Fecal Microbiota Transplantation on 8‐Week Remission in Patients With Ulcerative Colitis: A Randomized Clinical Trial. Jama. 2019; 321(2): 156‐ 64. 30644982 PMC6439766

200 of 218 shown

Authors
Lee, M.
Affiliations
Sun Yat-sen University (CN)
Corresponding author
Lee, Mong‐Hong
ORCID
Lee, Mong‐Hong
Venue
Cancer Communications
Publisher
American Association for the Advancement of Science (AAAS)
Published
2021-08-06
Volume
41
Issue
10
Pages
937-967
ISSN
  • 1000-467X (ISSN-L)
  • 2523-3548
DOI
10.1002/cac2.12200
PMC
PMC8504147
OpenAlex
W3189358902
Cited by
50
References
269
Citations by year
2026: 4 · 2025: 13 · 2024: 15 · 2023: 13 · 2022: 5
FWCI
0.86
Type
journal article
Language
en
Open access
Licence
Locations
  • 癌症：英文版 (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National key research and development program (2020YFA0803300, 2018YFC0910300)
  • National Natural Science Foundation of China (81630072)
  • China Association for Science and Technology (2018YFC0910300, 2020YFA0803300)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
Keywords
gut microbiota, carcinogenesis, dysbiosis, host-microbe interactions, cancer immunotherapy, chemosensitivity, antitumor immunity, genomic instability, cancer prevention, cancer diagnosis, metagenomics
MeSH terms
Gastrointestinal Microbiome, Humans, Neoplasms, Carcinogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review